- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.07. | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 13.07. | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| 13.07. | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| 13.07. | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan startet Kardigan-Aktie mit "Overweight" - Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com | ||
| 22.06. | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 339 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| 18.06. | Kardigan's IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases | 1 | MedCity News | ||
| 18.06. | Kardigan rises in Nasdaq debut after upsized $400 million IPO | 2 | Reuters | ||
| 18.06. | Kardigan rises on market debut after upsized IPO | 3 | Seeking Alpha | ||
| 18.06. | Heart drug biotech Kardigan raises $400m in upscaled IPO | 1 | pharmaphorum | ||
| 18.06. | Cardiovascular diseases biotech Kardigan prices upsized IPO at $16, the high end of the range | 2 | Renaissance Capital | ||
| 18.06. | Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 | 3 | FierceBiotech | ||
| 18.06. | Cardiovascular biotech Kardigan prices upsized $400M IPO at $16/share | 1 | Seeking Alpha | ||
| 18.06. | Kardigan prices IPO at $16 per share, raising $400 million | 2 | Investing.com | ||
| 18.06. | Kardigan, Inc. Announces Pricing of Upsized Initial Public Offering | 352 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,690 | -2,59 % | Innocan Pharma Corporation: Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth | The rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust.HERZLIYA, Israel and CALGARY, AB, July 29... ► Artikel lesen | |
| JAGUAR HEALTH | 1,010 | +1,00 % | Jaguar Health, Inc.: Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog | Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... ► Artikel lesen | |
| KALA BIO | 0,771 | +2,05 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,380 | -8,15 % | Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer | ||
| GALECTIN THERAPEUTICS | 3,160 | +22,48 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,080 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration | FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,650 | 0,00 % | Kazia files patent for breast cancer treatment strategy | ||
| INMED PHARMACEUTICALS | 1,250 | -11,35 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,580 | -1,53 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| MINDWALK | 1,170 | +2,63 % | MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure | Full-year revenue rose 46% to $15.6 million with gross margin expanding to 59%; net loss narrowed by more than half as MindWalk sharpened its focus on the BioIntelligence infrastructure powering... ► Artikel lesen | |
| LIPOCINE | 2,120 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,423 | -1,81 % | Heron Therapeutics, Inc.: Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 | ||
| HARROW | 32,200 | +1,26 % | Harrow, Inc.: Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 | ||
| INVENTIVA | 3,765 | 0,00 % | INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026 | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 - Inventiva (Euronext... ► Artikel lesen | |
| MEDICINOVA | 1,330 | 0,00 % | MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients | LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
KARDIGAN INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,05 % bei einem Aktienkurs von 20,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.